Piper Sandler Maintains Overweight on InspireMD, Raises Price Target to $4.5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Adam Maeder maintains an Overweight rating on InspireMD (NASDAQ:NSPR) and raises the price target from $3.5 to $4.5.
November 02, 2023 | 7:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler's Overweight rating on InspireMD is maintained and the price target is raised from $3.5 to $4.5.
The news is directly about InspireMD and is likely to have a positive impact on its stock price in the short term. The raised price target indicates the analyst's increased confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100